Epstein–Barr Viral Load is Associated to Response in AIDS-Related Lymphomas

详细信息    查看全文

• 作者：Paula Yurie Tanaka (1)
  Kouichi Ohshima (2)
  Masao Matsuoka (3)
  Ester Cerdeira Sabino (4)
  Suzete Cleusa Ferreira (4)
  Anna Shoko Nishya (4)
  Renata de Oliveira Costa (5)
  Edenilson Eduardo Calore (6)
  Nilda Maria Perez (6)
  Juliana Pereira (1) (5) (7)
  
• 关键词：Aids ; related lymphoma ; HIV ; EBV
• 刊名：Indian Journal of Hematology and Blood Transfusion
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：30
• 期：3
• 页码：191-194
• 全文大小：184 KB
• 参考文献：1. Goedert JJ (2000) The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 27(4):390-01
  2. Tanaka PY, Pracchia LF, Bellesso M, Chamone DA, Calore EE, Pereira J (2010) A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil. Ann Hematol 89(1):45-1 CrossRef
  3. Young LS, Murray PG (2003) Epstein–Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22(33):5108-121 CrossRef
  4. Bibas M, Antinori A (2009) EBV and HIV-related lymphoma. Mediterr J Hematol InfectDis 1(2):e2009032
  5. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F (2001) Dysfunctional Epstein–Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 98(1):146-55 CrossRef
  6. van Baarle D, Wolthers KC, Hovenkamp E, Niesters HG, Osterhaus AD, Miedema F, Van Oers MH (2002) Absolute level of Epstein–Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 186(3):405-09 CrossRef
  7. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Reportof an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244
  8. O’Sullivan CE, Peng R, Cole KS, Montelaro RC, Sturgeon T, Jenson HB, Ling PD (2002) Epstein–Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 67(3):320-26 CrossRef
  9. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML (2005) Epstein–Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 75(1):59-9 CrossRef
  10. Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, Morlat P, Beylot J, Fleury H, Lafon ME (2006) A longitudinal and prospective study of Epstein–Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 36(4):258-63 CrossRef
  11. Uner A, Akyurek N, Saglam A, Abdullazade S, Uzum N, Onder S, Barista I, Benekli M (2011) The presence of Epstein–Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on ‘EBV-positive DLBCL of the elderly- APMIS 119(4-):309-16 CrossRef
  12. Morales D, Beltran B, De Mendoza FH, Riva L, Yabar A, Qui?ones P, Butera JN, Castillo J (2010) Epstein–Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 51(1):66-2 CrossRef
  
• 作者单位：Paula Yurie Tanaka (1)
  Kouichi Ohshima (2)
  Masao Matsuoka (3)
  Ester Cerdeira Sabino (4)
  Suzete Cleusa Ferreira (4)
  Anna Shoko Nishya (4)
  Renata de Oliveira Costa (5)
  Edenilson Eduardo Calore (6)
  Nilda Maria Perez (6)
  Juliana Pereira (1) (5) (7)
  
  1. Faculdade de Medicina -Programa de Ciências Médicas, Universidade de S?o Paulo, Av. Dr. Arnaldo, 455, S?o Paulo, Brazil
  2. Department of Pathology, School of Medicine, Kurume University, 67 Asahi-machi, Kurume-shi, Fukuoka-ken, Japan
  3. Institute for Virus Research, Kyoto University, 53 Asahi-machi, Kurume-shi, Fukuoka-ken, Japan
  4. Laboratório de biologia molecular –Funda??o pró-sangue, Av. Dr. Enéas de Carvalho Aguiar, 155, S?o Paulo, Brazil
  5. Instituto do Cancer do Estado de S?o Paulo, Av. Dr. Arnaldo, 251, S?o Paulo, Brazil
  6. Pathology Section - Instituto de Infectologia Emílio Ribas, Av. Dr. Arnaldo, 165, S?o Paulo, Brazil
  7. Laboratório de Imunopatologia, Prédio de Ambulatórios do Hospital das Clinicas, Av. Dr. Enéas de Carvalho Aguiar, 255, 1o.andar, bloco 12 sala 61, Cep: 05403 -001, S?o Paulo, Brazil
  
• ISSN：0974-0449

文摘

AIDS-related lymphoma (ARL) development is associated to immunodeficiency state with proliferation of B-cells driven by HIV itself and EBV infection. However, Epstein–Barr DNA is not detected in malignant cells of all ARL subtypes. A prospective and controlled study to analyze EBV viral load (VL) in plasma and peripheral blood mononuclear cells (PBMC) of ARL patients was performed to analyze if Epstein–Barr VL could be related to response in these patients. Fifteen patients with ARL were included in this study with measurement of EBV VL at three different periods of time: at lymphoma diagnosis, upon completion of chemotherapy, and 3?months after. Two control groups composed by HIV-negative and HIV-positive patients were also evaluated for EBV VL comparison. In situ hybridization for EBER was performed on diagnostic samples of all ARL patients. Median EBV VL in PBMC and plasma had a significant decrease (p?=?0.022 and p?=?0.003, respectively) after ARL treatment. EBER was positive in 7 (46.7?%) cases. Median EBV VL in PBMC before lymphoma treatment in patients positive for EBER was significantly higher compared to EBER negative cases (p?=?0.041). Reduction of EBV viral load during treatment of lymphoma could be predictive of response. EBER expression was associated to advanced stages of disease and worse immune status. Our study suggests that measurement of EBV VL during ARL treatment could be used as a marker for response, but further studies are needed to validate this association.